This week, the PAX-D study reached the milestone of consenting its 100th participant across all nine participating centres.
Consenting to take part in the trial means a participant has read our Participant Information Sheet and has agreed to enter into the run-in phase ahead of randomisation, which is when they will be allocated to either the pramipexole condition or a placebo.
